Junyi Investment
君熠投资
Junyi Investment (君熠投资, also referred to as Wider Link Enterprise Investment Limited) is a fund that appears in elsewhere's corpus primarily as a participant in the $131 million pre-IPO round of Minghui Pharmaceutical in August 2025, co-led by Qiming Venture Partners and OrbiMed . Beyond this single disclosed investment, elsewhere's bundle contains no dedicated profile of the fund—no founding date, team composition, AUM, or stated strategy. The entity card lists it as a fund, but the retrieved chunks offer no further substance about Junyi Investment itself.
AI-generated — may contain errors, please verify.
Coverage
5Y News｜Minghui Pharma Closes $131 Million Pre-IPO Round to Accelerate Pipeline Development and Global Expansion
Dedicated to developing innovative therapies that address unmet clinical needs worldwide.
Minghui Pharmaceutical Raises $131M in Pre-IPO Round Co-Led by Qiming Venture Partners
Minghui Pharmaceutical is a late-stage biopharmaceutical company focused on oncology and autoimmune diseases.
